Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | NAMPT | P43490 | 12/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29467522 | 1.00 | EPHX2 (0.43) | EPHX2GPR119NAMPTUSP2SMN1; SMN2 | |
| SCHEMBL16925223 | 1.00 | EPHX2 (0.43) | EPHX2GPR119NAMPTUSP2SMN1; SMN2 | |
| SCHEMBL29455966 | 1.00 | EPHX2 (0.43) | EPHX2GPR119NAMPTUSP2SMN1; SMN2 | |
| SCHEMBL31184140 | 1.00 | EPHX2 (0.43) | EPHX2GPR119NAMPTUSP2SMN1; SMN2 | |
| SCHEMBL20337487 | 1.00 | EPHX2 (0.43) | EPHX2GPR119NAMPTUSP2SMN1; SMN2 | |
| SCHEMBL16925036 | 1.00 | EPHX2 (0.43) | EPHX2GPR119NAMPTUSP2SMN1; SMN2 | |
| SCHEMBL31184077 | 1.00 | EPHX2 (0.43) | EPHX2GPR119NAMPTUSP2SMN1; SMN2 | |
| SCHEMBL21064222 | 1.00 | EPHX2 (0.43) | EPHX2GPR119NAMPTUSP2SMN1; SMN2 | |
| SCHEMBL21631735 | 1.00 | EPHX2 (0.43) | EPHX2GPR119NAMPTUSP2SMN1; SMN2 | |
| SCHEMBL16925230 | 0.91 | EPHX2 (0.41) | EPHX2GPR119NAMPTEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308660-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2019-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308660-B2 | Compounds and compositions for inhibiting the activity of SHP2 | PTPN3, PTPN1, PTPN2 | EPHX2 2323/4885GPR119 716/4885NAMPT 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.